NASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis $1.26 +0.05 (+3.70%) Closing price 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About PMV Pharmaceuticals Stock (NASDAQ:PMVP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PMV Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.22▼$1.2950-Day Range$1.05▼$1.4252-Week Range$1.02▼$1.88Volume189,817 shsAverage Volume307,718 shsMarket Capitalization$67.20 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingModerate Buy Company Overview PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. Read More PMV Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScorePMVP MarketRank™: PMV Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 313th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingPMV Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPMV Pharmaceuticals has a consensus price target of $4.00, representing about 217.5% upside from its current price of $1.26.Amount of Analyst CoveragePMV Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about PMV Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PMV Pharmaceuticals are expected to grow in the coming year, from ($1.45) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.96% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 10.67, which indicates bearish sentiment.Change versus previous monthShort interest in PMV Pharmaceuticals has recently decreased by 1.75%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentPMV Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.15% of the stock of PMV Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PMV Pharmaceuticals' insider trading history. Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMVP Stock News HeadlinesPMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate HighlightsAugust 14 at 8:00 AM | globenewswire.comPMV Pharmaceuticals, Inc.August 13 at 12:12 AM | edition.cnn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 14 at 1:00 AM | Profits Run (Ad)PMV Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:PMVPJune 25, 2026 | benzinga.comPMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84April 28, 2026 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | finanznachrichten.dePMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | globenewswire.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?April 20, 2026 | finance.yahoo.comSee More Headlines PMVP Stock Analysis - Frequently Asked Questions How have PMVP shares performed this year? PMV Pharmaceuticals' stock was trading at $1.25 at the start of the year. Since then, PMVP stock has increased by 0.8% and is now trading at $1.26. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) released its earnings results on Friday, August, 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.05. When did PMV Pharmaceuticals IPO? PMV Pharmaceuticals (PMVP) raised $200 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 11,765,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO. Who are PMV Pharmaceuticals' major shareholders? PMV Pharmaceuticals' top institutional investors include BlackRock Inc. (1.72%), Walleye Capital LLC (0.63%), Assenagon Asset Management S.A. (0.62%) and ADAR1 Capital Management LLC (0.38%). Insiders that own company stock include Orbimed Advisors Llc, David Henry Mack, Robert Ticktin, Deepika Jalota and Michael Carulli. View institutional ownership trends. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC). Company Calendar Today8/14/2026Last Earnings8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 PMVP's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PMVP CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees50Year Founded2013Price Target and Rating Average Price Target for PMV Pharmaceuticals$4.00 High Price Target$5.00 Low Price Target$3.00 Potential Upside/Downside+217.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.98% Return on Assets-62.70% Debt Debt-to-Equity RatioN/A Current Ratio11.14 Quick Ratio11.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.97 per share Price / Book0.64Miscellaneous Outstanding Shares53,330,000Free Float47,919,000Market Cap$67.20 million OptionableOptionable Beta1.34 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:PMVP) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour 10X AI demo is starting…Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...TradeSmith | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredGold buyout deals have handed shareholders overnight gains up to 79 percentGold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...Golden Portfolio | SponsoredWho Really Gets Rich from IPOs?Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
